Edwards Lifesciences Corporation (EW) Price Target Increased to $14.00 by Analysts at SunTrust Banks, Inc.

Edwards Lifesciences Corporation (NYSE:EW) had its price objective lifted by SunTrust Banks, Inc. to $14.00 in a research report released on Monday morning, The Fly reports. They currently have a buy rating on the medical research company’s stock.

Several other analysts have also recently weighed in on the stock. Vetr cut shares of Edwards Lifesciences Corporation from a strong-buy rating to a buy rating and set a $105.74 price objective on the stock. in a research report on Monday, March 27th. Cowen and Company reiterated an outperform rating and issued a $120.00 target price on shares of Edwards Lifesciences Corporation in a research report on Tuesday, March 28th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corporation from a hold rating to a buy rating and set a $125.00 target price on the stock in a research report on Monday, May 22nd. Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a research report on Tuesday, May 16th. They issued a conviction-buy rating and a $138.00 target price on the stock. Finally, Evercore ISI upgraded shares of Edwards Lifesciences Corporation from an in-line rating to an outperform rating and lifted their target price for the stock from $98.50 to $110.00 in a research report on Monday, March 27th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. Edwards Lifesciences Corporation presently has a consensus rating of Buy and a consensus price target of $116.99.

Edwards Lifesciences Corporation (NYSE:EW) opened at 119.04 on Monday. The firm’s 50-day moving average is $117.29 and its 200 day moving average is $103.16. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.75. The firm has a market capitalization of $24.97 billion, a P/E ratio of 39.57 and a beta of 0.64.

Edwards Lifesciences Corporation (NYSE:EW) last posted its quarterly earnings data on Tuesday, April 25th. The medical research company reported $0.94 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.82 by $0.12. The firm had revenue of $883.50 million for the quarter, compared to analysts’ expectations of $776.51 million. Edwards Lifesciences Corporation had a net margin of 20.85% and a return on equity of 25.80%. The business’s quarterly revenue was up 26.7% on a year-over-year basis. During the same quarter last year, the company posted $0.71 EPS. On average, analysts expect that Edwards Lifesciences Corporation will post $3.53 EPS for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This article was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://sportsperspectives.com/2017/07/20/edwards-lifesciences-corporation-ew-price-target-increased-to-14-00-by-analysts-at-suntrust-banks-inc.html.

In related news, VP Bernard J. Zovighian sold 18,050 shares of the business’s stock in a transaction that occurred on Thursday, April 27th. The shares were sold at an average price of $109.21, for a total transaction of $1,971,240.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,600 shares of the business’s stock in a transaction that occurred on Thursday, June 29th. The shares were sold at an average price of $117.15, for a total transaction of $656,040.00. The disclosure for this sale can be found here. Insiders have sold 252,101 shares of company stock valued at $28,141,680 over the last three months. 2.13% of the stock is owned by corporate insiders.

A number of hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP raised its stake in shares of Edwards Lifesciences Corporation by 43.5% in the fourth quarter. GSA Capital Partners LLP now owns 3,354 shares of the medical research company’s stock valued at $314,000 after buying an additional 1,016 shares during the period. South Texas Money Management Ltd. raised its stake in shares of Edwards Lifesciences Corporation by 157.9% in the first quarter. South Texas Money Management Ltd. now owns 344,816 shares of the medical research company’s stock valued at $32,437,000 after buying an additional 211,119 shares during the period. Financial Counselors Inc. raised its stake in shares of Edwards Lifesciences Corporation by 2.1% in the first quarter. Financial Counselors Inc. now owns 13,637 shares of the medical research company’s stock valued at $1,283,000 after buying an additional 282 shares during the period. American Century Companies Inc. raised its stake in shares of Edwards Lifesciences Corporation by 7.2% in the first quarter. American Century Companies Inc. now owns 2,046,875 shares of the medical research company’s stock valued at $192,550,000 after buying an additional 137,934 shares during the period. Finally, Advisor Partners LLC raised its stake in shares of Edwards Lifesciences Corporation by 7.5% in the first quarter. Advisor Partners LLC now owns 4,895 shares of the medical research company’s stock valued at $460,000 after buying an additional 341 shares during the period. Institutional investors own 83.62% of the company’s stock.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

The Fly

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply